|
|
|
| home > white papers > Analysis of Biopharmaceuticals to Conform to ICHQ6B - RSSL |
|
|
 WHITE PAPERS |
|
RSSL
|
+44 (0)118 918 4024
|
|
http://www.rssl.com
|
|
University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA
|
|
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
|
|
Worldwide, the pharmaceuticals market is anticipated to grow from more
than USD 782 billion in 2011 to approach a value of just over USD 971
billion by the end of 2016, registering a CAGR of over 24%. In 2010 the
average medicines expenditure per person within the UK was £271, and
this is expected to increase with the ageing population. A significant
and increasing proportion of these sales are protein-based
biotherapeutics or biomolecules. Currently, these account for 19% of the
total market, and are growing at twice the rate of traditional small
molecule pharmaceuticals. It is predicted that close to 50% of the top
100 pharmaceutical products will be biomolecules by 2016. By far the
largest segment of the biopharmaceutical market is the monoclonal
antibody (MAb) with an estimated share of 25.6%, which corresponds to
USD 51.1 billion.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Registration Opens for Inaugural HPAPI USA Conference in October
The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >> |
|
 |
White Papers |
 |
|
The Promise and Challenge of Adaptive Design in Oncology Trials
Medpace
Clinical oncology trials are more complex and time consuming than those
in any other therapeutic area and failure rates are frustratingly high.
Given the urgent need for new oncologic therapies, sponsors are eager to
find more effective ways to conduct clinical research.
Incorporating adaptive design methodologies into clinical trials can
reduce costs and enhance efficiency while maintaining trial integrity.
They can also reduce the number of patients on placebo and
sub-therapeutic doses. In light of this promise, regulatory bodies have
created guidelines supportive of adaptive design.
More info >> |
|
 |
Industry Events |
 |
CPhI & P-MEC China
18-20 June 2019, SNIEC, Shanghai, China
CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >> |
|
|
|
